Theriva Biologics reports Q2 2025 financials, $12.1mln cash, VCN-01 data positive.

• Theriva Biologics releases positive topline data from VIRAGE Phase 2b study of VCN-01. • Expanded data to be presented at ESMO 2025 Congress in October. • VCN-01 shows potential in retinoblastoma with Phase 1 safety and clinical outcome data. • Cash and cash equivalents of $12.1 million as of June 30, 2025. • Expected cash runway into Q1 2026.

Theriva Biologics (NYSE American: TOVX) has announced positive topline data from its VIRAGE Phase 2b study of VCN-01. The study, which focuses on patients with pancreatic ductal adenocarcinoma (PDAC) metastásico, showed promising results in terms of survival, progression-free survival, and response duration compared to standard gemcitabine/nab-paclitaxel treatment [1].

The company expects to present expanded data from the VIRAGE study at the European Society for Medical Oncology (ESMO) 2025 Congress in October. Additionally, VCN-01 demonstrated potential in the treatment of retinoblastoma, with positive clinical and safety outcomes from a Phase 1 study presented at the 2025 American Society of Clinical Oncology (ASCO) meeting [1].

Theriva Biologics reported $12.1 million in cash and cash equivalents as of June 30, 2025, with sufficient liquidity to fund operations until the first quarter of 2026 [1]. The company's CEO, Steven A. Shallcross, expressed optimism about the progress made in the first half of 2025 and the potential for VCN-01 to advance into Phase 3 clinical trials for PDAC and other indications [1].

References:
[1] Theriva Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2025. [https://www.globenewswire.com/news-release/2025/08/11/3130834/0/es/Theriva-Biologics-presenta-los-aspectos-operativos-m%C3%A1s-destacados-y-los-resultados-financieros-del-segundo-trimestre-de-2025.html](https://www.globenewswire.com/news-release/2025/08/11/3130834/0/es/Theriva-Biologics-presenta-los-aspectos-operativos-m%C3%A1s-destacados-y-los-resultados-financieros-del-segundo-trimestre-de-2025.html)